clinical trial · NCT05032196
Study of WVE-003 in Patients With Huntington's Disease
Huntington DiseaseSAD: 30mg WVE-003SAD: 60mg WVE-003SAD: 90mg WVE-003SAD: Pooled PlaceboMD: 30mg WVE-003MD: Placebo
brief summary
This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of WVE-003 in adult patients with early-manifest HD who carry the targeted single nucleotide polymorphism (SNP) - SNP3.
started
Sep 6, 2021
primary completion
May 24, 2024
completion
May 24, 2024
last updated
Aug 12, 2025
official title
A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington's Disease (SELECT-HD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol